174 related articles for article (PubMed ID: 37077937)
21. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.
Hessenkemper W; Roediger J; Bartsch S; Houtsmuller AB; van Royen ME; Petersen I; Grimm MO; Baniahmad A
Mol Endocrinol; 2014 Nov; 28(11):1831-40. PubMed ID: 25203674
[TBL] [Abstract][Full Text] [Related]
22. Loss and revival of androgen receptor signaling in advanced prostate cancer.
Formaggio N; Rubin MA; Theurillat JP
Oncogene; 2021 Feb; 40(7):1205-1216. PubMed ID: 33420371
[TBL] [Abstract][Full Text] [Related]
23. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.
Xu D; Lin TH; Li S; Da J; Wen XQ; Ding J; Chang C; Yeh S
Cancer Lett; 2012 Mar; 316(1):11-22. PubMed ID: 22154085
[TBL] [Abstract][Full Text] [Related]
24. Antagonistic action of a synthetic androgen ligand mediated by chromatin remodeling in a human prostate cancer cell line.
Sawada T; Kanemoto Y; Amano R; Hayakawa A; Kurokawa T; Mori J; Kato S
Biochem Biophys Res Commun; 2022 Jul; 612():110-118. PubMed ID: 35523048
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
26. Structurally distinct PARP7 inhibitors provide new insights into the function of PARP7 in regulating nucleic acid-sensing and IFN-β signaling.
Sanderson DJ; Rodriguez KM; Bejan DS; Olafsen NE; Bohn ID; Kojic A; Sundalam S; Siordia IR; Duell AK; Deng N; Schultz C; Grant DM; Matthews J; Cohen MS
Cell Chem Biol; 2023 Jan; 30(1):43-54.e8. PubMed ID: 36529140
[TBL] [Abstract][Full Text] [Related]
27. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
[TBL] [Abstract][Full Text] [Related]
28. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.
Gozgit JM; Vasbinder MM; Abo RP; Kunii K; Kuplast-Barr KG; Gui B; Lu AZ; Molina JR; Minissale E; Swinger KK; Wigle TJ; Blackwell DJ; Majer CR; Ren Y; Niepel M; Varsamis ZA; Nayak SP; Bamberg E; Mo JR; Church WD; Mady ASA; Song J; Utley L; Rao PE; Mitchison TJ; Kuntz KW; Richon VM; Keilhack H
Cancer Cell; 2021 Sep; 39(9):1214-1226.e10. PubMed ID: 34375612
[TBL] [Abstract][Full Text] [Related]
29. 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD)-Inducible Poly-ADP-Ribose Polymerase (TIPARP/PARP7) Catalytic Mutant Mice (TiparpH532A) Exhibit Increased Sensitivity to TCDD-Induced Hepatotoxicity and Lethality.
Hutin D; Long AS; Sugamori K; Shao P; Singh SK; Rasmussen M; Olafsen NE; Pettersen S; Grimaldi G; Grant DM; Matthews J
Toxicol Sci; 2021 Aug; 183(1):154-169. PubMed ID: 34129049
[TBL] [Abstract][Full Text] [Related]
30. Loss of PARP7 Increases Type I Interferon Signaling in EO771 Breast Cancer Cells and Prevents Mammary Tumor Growth by Increasing Antitumor Immunity.
Rasmussen M; Alvik K; Kannen V; Olafsen NE; Erlingsson LAM; Grimaldi G; Takaoka A; Grant DM; Matthews J
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509350
[TBL] [Abstract][Full Text] [Related]
31. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Bhattacharyya RS; Krishnan AV; Swami S; Feldman D
Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
[TBL] [Abstract][Full Text] [Related]
32. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
34. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
35. Quantification of PARP7 Protein Levels and PARP7 Inhibitor Target Engagement in Cells Using a Split Nanoluciferase System.
Duell AK; Sanderson DJ; Cohen MS
Methods Mol Biol; 2023; 2609():387-395. PubMed ID: 36515849
[TBL] [Abstract][Full Text] [Related]
36. Cross-talk between androgen receptor and pregnane and xenobiotic receptor reveals existence of a novel modulatory action of anti-androgenic drugs.
Kumar S; Jaiswal B; Kumar S; Negi S; Tyagi RK
Biochem Pharmacol; 2010 Oct; 80(7):964-76. PubMed ID: 20599793
[TBL] [Abstract][Full Text] [Related]
37. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.
Terry S; Yang X; Chen MW; Vacherot F; Buttyan R
J Cell Biochem; 2006 Oct; 99(2):402-10. PubMed ID: 16741972
[TBL] [Abstract][Full Text] [Related]
38. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
Gan L; Chen S; Wang Y; Watahiki A; Bohrer L; Sun Z; Wang Y; Huang H
Cancer Res; 2009 Nov; 69(21):8386-94. PubMed ID: 19826044
[TBL] [Abstract][Full Text] [Related]
40. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.
Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC
J Biomed Sci; 2011 Aug; 18(1):63. PubMed ID: 21859492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
